|Previous Section||Index||Home Page|
11 Feb 2003 : Column 666Wcontinued
Mr. Burstow: To ask the Secretary of State for health pursuant to his answer of 20 January 2003, Official Report, column 120W, on contractor fraud, how much money has been recovered in each of the last three years. 
|Year||Value of Recovery (£)|
Ms Blears: Erythropoietin for chemotherapy induced anaemia is being considered as part of the National Institute for Clinical Excellence's ninth wave work programme, the contents of which will be announced later this year.
Dr. Evan Harris: To ask the Secretary of State for Health how many local research ethics committee administrators resigned between (a) 1 April 2001 and 31 March 2002, and (b) 1 April and 30 November 2002. 
Mr. Lammy: Administrators for local research ethics committees are employed locally, and personnel records are not held centrally. From 1 October 2002, however, the Central Office for Research Ethics Committees has monitored the resignation, appointment and training of administrators.
11 Feb 2003 : Column 667W
Mr. Lammy: There is at present no United Kingdom ethics committee authority. Directive 2001/20/EC required United Kingdom-wide opinions on the ethics of proposals for clinical trials involving medicinal products for human use from May 2004. After consultation in 2003, draft regulations implementing Directive 2001/20/EC will be laid before Parliament.
Tim Loughton: To ask the Secretary of State for Health what assessment has been made of the implications for (a) specialist manufacturers, (b) specialist retailers and (c) consumer choice of the requirement to remove from the market the nutrients and nutrient sources which are not listed as acceptable for such use under the schedules to the proposed Food Supplements (England) Regulations 2003. 
Ms Blears: The regulations will not require the immediate removal from the market of food supplements containing nutrients and nutrient sources excluded from the lists in Schedules 2 and 3, which have been drawn directly from Annexes I and II in the directive. Therefore, in the short-term there is likely to be little, if any, impact upon specialist manufacturers, specialist retailers or consumer choice.
In implementing the directive, the Government are able, for a limited period of time, to allow continued use of substances not on the permitted lists, andwith very few exceptionsthey intend to do so.
Ms Blears: My noble Friend, the Parliamentary Under-Secretary of State (the Lord Hunt of Kings Heath) and I last met formally with representatives of the food supplements industry in July 2002 to discuss concerns over the possible impact of the EU food supplements directive on the UK industry. At present, Ministers have no plans for further meetings about this, but are always willing to meet stakeholders when circumstances have changed or there are new issues to be raised.
My noble Friend and I have held discussions with a wide range of stakeholders in the herbal sector on a number of occasions over the last year to discuss the proposed directive on traditional herbal medicinal products. Latterly, my noble Friend attended a meeting of stakeholders at the Medicines Control Agency on 10 October 2002. He met a number of trade associations on 21 November 2002 and representatives of Consumers for Health Choice, Holland and Barrett and
11 Feb 2003 : Column 668W
general nutrition centres on 28 November 2002. He also attended a Consumers for Health Choice Parliamentary Reception on 4 December 2002.
Mr. Laws: To ask the Secretary of State for Health how much money has been lost by his Department and its agencies and non-departmental public bodies through (a) fraud and (b) theft for each year since 199697. 
|Department||Agencies||Non-departmental public bodies|
Ms Blears: Decision making in medicines regulation is based on the comparative evaluation of the risks and the benefits of individual products. All available data in relation to the risk of hepatotoxicity associated with kava-kava was carefully considered, taking into account the evidence of benefits of treatment.
The risk assessment for kava-kava was considered by the Committee on Safety of Medicine (CSM), an expert subgroup of the CSM, which included independent experts in herbal medicine, clinical pharmacology and liver disease and the Medicines Commission. In total these committees have considered the safety of kava-kava in depth on five separate o ccasions since December 2001.
The CSM and the Medicines Commission considered a comparative assessment of the risks of kava-kava and benzodiazepines such as bromazepam, oxazepam and diazepam. Following consideration of all available data, these advisory committees considered the level of risk of hepatotoxicity associated with kava-kava to be unacceptable.
Tim Loughton: To ask the Secretary of State for Health whether massage oils containing extract of kava-kava plant applied to the scalp for relief of stress will be exempt from the terms of the Medicines for Human Use (Kava-Kava) Prohibition Order 2002. 
11 Feb 2003 : Column 669W
Ms Blears: Massage oils are not normally regarded as medicinal products by the Medicines Control Agency, but this depends on their ingredients and the claims made for them. However, medicinal products for external use are excluded from the scope of the Medicines for Human Use (Kava-Kava) Prohibition Order 2002. Accordingly, the Order does not cover massage oils containing kava-kava which are medicinal products.
Budgets for subsequent years have not yet been finalised. However, it is anticipated that additional resources will be made available during the three year period from 200304 to 200506 in order to fund specific initiatives to be taken forward by the Modernisation Agency.
Ms Blears: The Cabinet Office strategy unit and the Department of Health conducted a joint consultation exercise on the national alcohol harm reduction strategy. This consultation exercise ran from 15 October 2002 to 15 January 2003. 319 responses were received.
Tim Loughton: To ask the Secretary of State for Health what estimate he has made of the number of operations carried out by NHS hospital trusts in England in the last year which have resulted in retained instruments left inside the patients. 
The Government have established the national patient safety agency to improve the safety of NHS patient care by promoting an open and fair culture and by introducing a national reporting and learning system for adverse events. It is planned for the system to be rolled out across the NHS from summer 2003. The reporting and learning system will, in time, enable us to understand the nature and extent of adverse events in the NHS, including material retained within patients, and take action to prevent them from being repeated.
11 Feb 2003 : Column 670W
|Next Section||Index||Home Page|